company background image
RGS logo

Regeneus ASX:RGS Stock Report

Last Price

AU$0.005

Market Cap

AU$1.5m

7D

0%

1Y

-54.5%

Updated

28 Mar, 2024

Data

Company Financials

RGS Stock Overview

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia.

RGS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Regeneus Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneus
Historical stock prices
Current Share PriceAU$0.005
52 Week HighAU$0.02
52 Week LowAU$0.003
Beta-0.24
1 Month Change-16.67%
3 Month Change66.67%
1 Year Change-54.55%
3 Year Change-95.65%
5 Year Change-95.24%
Change since IPO-98.15%

Recent News & Updates

Recent updates

Have Insiders Been Buying Regeneus Ltd (ASX:RGS) Shares?

Nov 30
Have Insiders Been Buying Regeneus Ltd (ASX:RGS) Shares?

Shareholder Returns

RGSAU BiotechsAU Market
7D0%4.0%1.3%
1Y-54.5%1.2%11.5%

Return vs Industry: RGS underperformed the Australian Biotechs industry which returned 1.4% over the past year.

Return vs Market: RGS underperformed the Australian Market which returned 11.6% over the past year.

Price Volatility

Is RGS's price volatile compared to industry and market?
RGS volatility
RGS Average Weekly Movement32.4%
Biotechs Industry Average Movement11.5%
Market Average Movement8.8%
10% most volatile stocks in AU Market17.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: RGS's share price has been volatile over the past 3 months.

Volatility Over Time: RGS's weekly volatility has decreased from 41% to 32% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2007n/aKarolis Rosickashttps://regeneus.com.au

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company’s platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing.

Regeneus Ltd Fundamentals Summary

How do Regeneus's earnings and revenue compare to its market cap?
RGS fundamental statistics
Market capAU$1.53m
Earnings (TTM)-AU$366.01k
Revenue (TTM)AU$988.43k

1.6x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGS income statement (TTM)
RevenueAU$988.43k
Cost of RevenueAU$0
Gross ProfitAU$988.43k
Other ExpensesAU$1.35m
Earnings-AU$366.01k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0012
Gross Margin100.00%
Net Profit Margin-37.03%
Debt/Equity Ratio0%

How did RGS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.